Literature DB >> 26995001

Diarrhea-associated hemolytic uremic syndrome with severe neurological manifestations treated with IgG depletion through immunoadsorption.

Benjamin Flam1, Peter Sackey2,3, Andreas Berge4, Anne C Zachau5, Bo Brink6, Sigrid Lundberg6,7.   

Abstract

BACKGROUND: Diarrhea-associated hemolytic uremic syndrome (HUS) is characterized by acute kidney injury with microangiopathic hemolytic anemia and thrombocytopenia with a diarrhea prodrome, typically caused by Shiga-like toxin-producing Escherichia coli. Supportive management is generally recommended. CASE REPORT: A 58-year-old female with diarrhea-associated HUS developed delayed-onset severe neurological manifestations including coma, status epilepticus, and subcortical magnetic resonance imaging signal alterations. Rescue treatment with immunoglobulin (Ig)G depletion through immunoadsorption was followed by significant improvement in neurological and renal function. The patient recovered with only minimal sequelae.
CONCLUSION: Delayed-onset neurological abnormalities may occur in diarrhea-associated HUS. Novel specific treatment options include IgG depletion through immunoadsorption. Severe clinical and imaging findings do not preclude a good outcome.

Entities:  

Keywords:  Coma; Hemolytic-uremic syndrome; IgG depletion; Immunoadsorption; Shiga-toxigenic Escherichia coli; Status epilepticus

Mesh:

Substances:

Year:  2016        PMID: 26995001     DOI: 10.1007/s40620-016-0294-5

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  11 in total

1.  [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia].

Authors:  C GASSER; E GAUTIER; A STECK; R E SIEBENMANN; R OECHSLIN
Journal:  Schweiz Med Wochenschr       Date:  1955-09-20

2.  Immunoadsorption in patients with haemolytic uraemic syndrome.

Authors:  Christian Combe; Hoang-Nam Bui; Valérie de Précigout; Gilles Hilbert; Yahsou Delmas
Journal:  Lancet       Date:  2012-02-11       Impact factor: 79.321

Review 3.  Conventional apheresis therapies: a review.

Authors:  David M Ward
Journal:  J Clin Apher       Date:  2011-08-31       Impact factor: 2.821

4.  How I treat patients with thrombotic thrombocytopenic purpura: 2010.

Authors:  James N George
Journal:  Blood       Date:  2010-08-04       Impact factor: 22.113

5.  Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome.

Authors:  Maurizio Brigotti; Pier Luigi Tazzari; Elisa Ravanelli; Domenica Carnicelli; Laura Rocchi; Valentina Arfilli; Gaia Scavia; Fabio Minelli; Francesca Ricci; Pasqualepaolo Pagliaro; Alfonso V S Ferretti; Carmine Pecoraro; Fabio Paglialonga; Alberto Edefonti; Maria Antonietta Procaccino; Alberto E Tozzi; Alfredo Caprioli
Journal:  Pediatr Infect Dis J       Date:  2011-06       Impact factor: 2.129

6.  Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study.

Authors:  Edin Colic; Hans Dieperink; Kjell Titlestad; Martin Tepel
Journal:  Lancet       Date:  2011-08-24       Impact factor: 79.321

7.  Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome.

Authors:  Sylvie Nathanson; Thérésa Kwon; Monique Elmaleh; Marina Charbit; Emma Allain Launay; Jérôme Harambat; Muriel Brun; Bruno Ranchin; Flavio Bandin; Sylvie Cloarec; Guylhene Bourdat-Michel; Christine Piètrement; Gérard Champion; Tim Ulinski; Georges Deschênes
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

8.  Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial.

Authors:  Andreas Greinacher; Sigrun Friesecke; Peter Abel; Alexander Dressel; Sylvia Stracke; Michael Fiene; Friedlinde Ernst; Kathleen Selleng; Karin Weissenborn; Bernhard M W Schmidt; Mario Schiffer; Stephan B Felix; Markus M Lerch; Jan T Kielstein; Julia Mayerle
Journal:  Lancet       Date:  2011-09-02       Impact factor: 79.321

9.  Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome.

Authors:  N Cimolai; B J Morrison; J E Carter
Journal:  Pediatrics       Date:  1992-10       Impact factor: 7.124

Review 10.  Renal and neurological involvement in typical Shiga toxin-associated HUS.

Authors:  Howard Trachtman; Catherine Austin; Maria Lewinski; Rolf A K Stahl
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

View more
  3 in total

1.  A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.

Authors:  Paolo Giordano; Giuseppe Stefano Netti; Luisa Santangelo; Giuseppe Castellano; Vincenza Carbone; Diletta Domenica Torres; Marida Martino; Michela Sesta; Franca Di Cuonzo; Maria Chiara Resta; Alberto Gaeta; Leonardo Milella; Maria Chironna; Cinzia Germinario; Gaia Scavia; Loreto Gesualdo; Mario Giordano
Journal:  Pediatr Nephrol       Date:  2018-10-25       Impact factor: 3.714

2.  Steroid Pulse Therapy for Severe Central Nervous System Involvement in Shiga Toxin-Producing Escherichia coli-Related Hemolytic Uremic Syndrome.

Authors:  Chiara Rosazza; Alberto M Cappellari; Cristiano Gandini; Elisa Scola; Gianluigi Ardissino
Journal:  Case Rep Pediatr       Date:  2021-05-15

3.  Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic Escherichia coli.

Authors:  Jorge Goldstein; Krista Nuñez-Goluboay; Alipio Pinto
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.